Credit Suisse’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-1,545,951
| Closed | -$30.1M | – | 4283 |
|
|
2018
Q1 | $30.1M | Sell |
1,545,951
-270,535
| -15% | -$5.31M | 0.03% | 644 |
|
|
2017
Q4 | $30.2M | Buy |
1,816,486
+1,719,764
| +1,778% | +$31.5M | 0.03% | 652 |
|
|
2017
Q3 | $1.96M | Buy |
96,722
+39,456
| +69% | +$754K | ﹤0.01% | 2558 |
|
|
2017
Q2 | $921K | Sell |
57,266
-25,568
| -31% | -$378K | ﹤0.01% | 2758 |
|
|
2017
Q1 | $1.05M | Sell |
82,834
-312,605
| -79% | -$3.78M | ﹤0.01% | 2830 |
|
|
2016
Q4 | $5.24M | Buy |
395,439
+315,022
| +392% | +$5.39M | 0.01% | 1615 |
|
|
2016
Q3 | $1.91M | Sell |
80,417
-27,820
| -26% | -$748K | ﹤0.01% | 2413 |
|
|
2016
Q2 | $3.12M | Buy |
108,237
+55,811
| +106% | +$1.82M | ﹤0.01% | 2013 |
|
|
2016
Q1 | $1.68M | Sell |
52,426
-69,823
| -57% | -$2.45M | ﹤0.01% | 2337 |
|
|
2015
Q4 | $5.23M | Buy |
122,249
+4,460
| +4% | +$178K | 0.01% | 1549 |
|
|
2015
Q3 | $4.15M | Sell |
117,789
-16,819
| -12% | -$758K | 0.01% | 1689 |
|
|
2015
Q2 | $6.18M | Buy |
134,608
+74,245
| +123% | +$3.52M | 0.01% | 1577 |
|
|
2015
Q1 | $2.83M | Buy |
60,363
+8,284
| +16% | +$330K | ﹤0.01% | 2101 |
|
|
2014
Q4 | $1.65M | Sell |
52,079
-31,822
| -38% | -$931K | ﹤0.01% | 2710 |
|
|
2014
Q3 | $1.99M | Sell |
83,901
-14,439
| -15% | -$370K | ﹤0.01% | 2495 |
|
|
2014
Q2 | $2.95M | Sell |
98,340
-16,206
| -14% | -$437K | ﹤0.01% | 2392 |
|
|
2014
Q1 | $3.03M | Sell |
114,546
-1,669
| -1% | -$41.7K | ﹤0.01% | 2194 |
|
|
2013
Q4 | $2.92M | Buy |
116,215
+6,579
| +6% | +$147K | ﹤0.01% | 2333 |
|
|
2013
Q3 | $2.24M | Buy |
109,636
+43,777
| +66% | +$904K | ﹤0.01% | 2284 |
|
|
2013
Q2 | $1.31M | Buy |
+65,859
| New | +$1.17M | ﹤0.01% | 2585 |
|
Credit Suisse's IPXL Position: Q2 2018 in Review
Credit Suisse sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 1,545,951 shares — an estimated $30.1M sold.
Credit Suisse first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $30.2M in Q4 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Credit Suisse reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Credit Suisse sold 1,545,951 Impax Laboratories, Inc. shares in Q2 2018, an estimated $30.1M.
- Credit Suisse first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Credit Suisse's Impax Laboratories, Inc. position peaked at $30.2M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.